Robert Huddart
The Royal Marsden NHS Foundation Trust
CancerInternal medicineRadiologyUrologySurgeryPathologyOncologyTesticular cancerChemotherapyGerm cell tumorsSeminomaCisplatinMEDLINEProstate cancerBladder cancerCarboplatinRadiation therapyClinical trialGeneticsMedicineBiology
Publications 505
#2A. Bajaj (NU: Northwestern University)
Last. Peter Hoskin (NU: Northwood University)H-Index: 94
view all 0 authors...
Abstract null null Bladder preservation with trimodality treatment (TMT) is an alternative strategy to radical cystectomy (RC) for the management of localised muscle invasive bladder cancer (MIBC). TMT comprises of transurethral resection of the bladder tumour (TURBT) followed by radiotherapy with concurrent radiosensitisation. TMT studies have shown neo-adjuvant chemotherapy with cisplatin-based regimens is often given to further improve survival outcomes. A hypofractionated radiotherapy regime...
#1Clare MoynihanH-Index: 27
#2Robert HuddartH-Index: 83
#1Sophie R. de Mol van Otterloo (UU: Utrecht University)H-Index: 1
Last. Corinne Faivre-Finn (University of Manchester)H-Index: 50
view all 36 authors...
ABSTRACT null null INTRODUCTION null : High-field MR-Linacs, linear accelerators (linac) combined with a diagnostic MRI scanner and online adaptive workflow, potentially give rise to novel online anatomic and response adaptive radiotherapy paradigms. Since the first high-field (1.5T) MR-Linac received regulatory approval in late 2018, little is known about clinical use, patient tolerability of daily high-field MRIs, and toxicity of treatments. Herein we report the initial experience within XXX (...
#1Thomas Powles (QMUL: Queen Mary University of London)H-Index: 84
#2Tibor CsősziH-Index: 10
view all 244 authors...
BACKGROUND PD-1 and PD-L1 inhibitors are active in metastatic urothelial carcinoma, but positive randomised data supporting their use as a first-line treatment are lacking. In this study we assessed outcomes with first-line pembrolizumab alone or combined with chemotherapy versus chemotherapy for patients with previously untreated advanced urothelial carcinoma. METHODS KEYNOTE-361 is a randomised, open-label, phase 3 trial of patients aged at least 18 years, with untreated, locally advanced, unr...
4 CitationsSource
#1Robert Huddart (ICR: Institute of Cancer Research)H-Index: 83
#2Shaista Hafeez (ICR: Institute of Cancer Research)H-Index: 13
Last. Hybrid InvestigatorsH-Index: 1
view all 24 authors...
Purpose Hypofractionated radiation therapy can be used to treat patients with muscle-invasive bladder cancer unable to have radical therapy. Toxicity is a key concern, but adaptive plan-of the day (POD) image-guided radiation therapy delivery could improve outcomes by minimizing the volume of normal tissue irradiated. The HYBRID trial assessed the multicenter implementation, safety, and efficacy of this strategy. Methods HYBRID is a Phase II randomized trial that was conducted at 14 UK hospitals...
8 CitationsSource
#1Syed A. Hussain (University of Sheffield)H-Index: 32
#2Nuria Porta (The Royal Marsden NHS Foundation Trust)
Last. Nicholas D. James (The Royal Marsden NHS Foundation Trust)H-Index: 66
view all 7 authors...